Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
54.09 K
Value Traded
47.17 K
Short % Float
1.91%
Days to Cover
1.0
0%Week
0%1 Month
0%3 Month
0%6 Month
0%5 Year
-96.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
53.65 M
EPS (TTM)
-1.07
P/E Ratio
-
Ent. Value
-21.99 M
Total Shares
60.97 M
Float Shares
39.45 M
Insiders
35.30%
Institutions
22.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
KRON Catalyst Timeline
Dated clinical, regulatory and corporate events for Kronos Bio, Inc.
Past FDA Catalysts and PDUFA Decisions
How KRON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | KB-9558 | IND Submission | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every KRON program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| KB-0742 | transcriptionally addicted solid tumors | Phase 1 | 2023-11-13 | demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in pre-treated patientsRead More | Document Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1 2 KB-0742 study at the AACR-NCI-EORead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KNOBELMAN DEBORAHOfficer (President & Interim CEO) | Sell | -24,838 139,422 held | $0.87 | 06/05/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in KRON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % | 1.11 M | 1.35 M | 34.09% ( 342.03 K) |
Ownership Trends
KRON Short Interest
Shares sold short, counted twice a month.
1.91%
Short % of Float
of tradable shares sold short
877.5K
Shares Sold Short
+16.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KRON ranks across every disease it competes in
Competitive Position is a premium feature
See how KRON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKRON News
About Kronos Bio, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next KRON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime